{
    "nct_id": "NCT05379985",
    "official_title": "A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS",
    "inclusion_criteria": "* Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).\n* Received prior standard therapy appropriate for tumor type and stage\n* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Primary central nervous system (CNS) tumors\n* Active, untreated brain metastases\n* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication\n* History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy\n\nOther inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}